产品
编 号：F390110
分子式：C12H30Br2N2
分子量：362.19
分子式：C12H30Br2N2
分子量：362.19
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
320
In-stock
1g
400
In-stock
5g
640
In-stock
结构图
CAS No: 55-97-0
产品详情
生物活性：
Hexamethonium Bromide is a non-selective ganglionic nicotinic-receptor antagonist (nAChR) antagonist, with mixed competitive and noncompetitive activity. Hexamethonium Bromide has anti-hypertensive activity. Hexamethonium Bromide attenuates sympathetic activity and blood pressure in spontaneously hypertensive animal models.
体内研究：
Hexamethonium Bromide (0.2-25 mg/kg; i.v.) significantly reduces therenal sympathetic nerve activity (RSNA), mean arterial pressure (MAP) and heart rate (HR) in the Wistar rats and the spontaneously hypertensive rats (SHRs).Hexamethonium Bromide (0.2-1.0 mg/kg; i.v.) treatments show no significant differences in the RSNA, MAP or HR between Wistar rats and SHRs.Hexamethonium Bromide (5.0-25 mg/kg; i.v.) results in a greater reduction in the RSNA and MAP in SHRs compared with Wistar rats.Animal Model:Male normotensive Wistar rats (280-320 g), SHRs
Dosage:0.2 mg/kg, 1.0 mg/kg, 5.0 mg/kg, 25 mg/kg
Administration:Intravenous injection
Result:Significantly reduced the RSNA, MAP and HR in the Wistar rats and the SHRs.
体外研究：
Hexamethonium Bromide (100 μM; 60 minutes) abolishes epibatidine-induced depolarisations of smooth muscle cells.The α3β4α5 receptors have greater sensitivity to Hexamethonium Bromide than the other potential ganglionic models, α3β4, α3β2, and α3β2α5.
Hexamethonium Bromide is a non-selective ganglionic nicotinic-receptor antagonist (nAChR) antagonist, with mixed competitive and noncompetitive activity. Hexamethonium Bromide has anti-hypertensive activity. Hexamethonium Bromide attenuates sympathetic activity and blood pressure in spontaneously hypertensive animal models.
体内研究：
Hexamethonium Bromide (0.2-25 mg/kg; i.v.) significantly reduces therenal sympathetic nerve activity (RSNA), mean arterial pressure (MAP) and heart rate (HR) in the Wistar rats and the spontaneously hypertensive rats (SHRs).Hexamethonium Bromide (0.2-1.0 mg/kg; i.v.) treatments show no significant differences in the RSNA, MAP or HR between Wistar rats and SHRs.Hexamethonium Bromide (5.0-25 mg/kg; i.v.) results in a greater reduction in the RSNA and MAP in SHRs compared with Wistar rats.Animal Model:Male normotensive Wistar rats (280-320 g), SHRs
Dosage:0.2 mg/kg, 1.0 mg/kg, 5.0 mg/kg, 25 mg/kg
Administration:Intravenous injection
Result:Significantly reduced the RSNA, MAP and HR in the Wistar rats and the SHRs.
体外研究：
Hexamethonium Bromide (100 μM; 60 minutes) abolishes epibatidine-induced depolarisations of smooth muscle cells.The α3β4α5 receptors have greater sensitivity to Hexamethonium Bromide than the other potential ganglionic models, α3β4, α3β2, and α3β2α5.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备